Use access key #2 to skip to page content.
$38.89 4.68 (13.68%)
10/13/2008 4:00 PM

Alexion Pharmaceuticals, Inc. (ALXN)

CAPS Rating:
*

A biotechnology company working to develop and deliver life-changing drug therapies for patients with serious and life-threatening medical conditions.

X

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating ALXN

Add Stock to Watchlist

What the Community Thinks

Total Members

81 Outperforms
31 Underperforms
 

All-Stars

15 Outperforms
16 Underperforms
 

Wall Street

10 Outperforms
0 Underperforms
 

Members bullish on ALXN are also bullish on:

Members bearish on ALXN are also bearish on:

Ticker Tags

Small Cap (1922), Drug Manufacturers - Other (105), Biotechnology (295)
Suggest a tag

Alexion Pharmaceuticals, Inc. At A Glance

Current Price: $38.89
Last Trade Time: 10/13/2008 4:00 PM
Open: $34.75
Previous Close: $34.21
Daily Range: $34.75 - $38.95
52-Week Range: $24.63 - $47.96
Volume: 1,636,755
Market Cap: $2.66B
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

ALXN VS S&P 500 (SPY)

ALXN 12 month chart vs. S&P

News & Discussion Boards

Other News Headlines for ALXN

More Headlines...

Top Bull Pitch

Recs

1

Alexion Pharmaceuticals, Inc. (ALXN)

Avatar SapphireSeas (76.53) Submitted: 10/04/07 1:42 PM


Reuters, 10/4/07:

In a departure from the current status quo, Presidential front runner Senator Hillary Clinton would support stem cell funding and research.

That would be a boon for research efforts and for companies such as ALXN, which specializes in the development of ...More

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

1

Alexion Pharmaceuticals, Inc. (ALXN)

Avatar abetens2 (97.90) Submitted: 4/29/08 8:38 AM

Paroxysmal Nocturnal Hemoglobinuria -- extremely rare condition. Can Alexion justify an extremely high price for because of the rarity of the disease? Probably not. Notice that they are recording sales but not receiving cash. Their accounts receivables are going up, because they are not collecti...More

Replies: 0 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 13 :   1 2 3 Next »

Recs

0

 (ALXN)

Avatar InvestRx (90.95) Submitted: 10/12/08 8:59 PM : Outperform Start Price: $34.75 ALXN Score: 5.15

Who's Next in the Biotech Buyout Frenzy?
The biotech industry is rapidly consolidating as big pharma companies put their cash stash to use in deals ranging from well-known large caps all the way down to unknown micro-caps in an effort to bolster their range of marketed products, late stage pipeline candidates, and drug discovery technology platforms.

Genentech (DNA) has rejected Roche's (RHHBY) $89 bid to acquire the remaining 44% of DNA it does not already own as insufficient. I think DNA could easily get $100 per share based on Eli Lilly's (LLY) $70 buyout of ImClone Systems (IMCL), which trumped Erbitux marketing partner Bristol-Myers' (BMY) raised bid of $62 per share. Also, several buyouts in the out-of-favor small and micro-cap biotech space have been announced over the past year with 100%-plus takeover premiums, including under-the-radar names such as:

(1.) SGX Pharma (SGXP) was acquired for $64M cash by Lilly for its cancer drug discovery platform

(2.) Kosan Biosciences (KOSN) was acquired by Bristol-Myers for its cancer drug pipeline

(3.) Barrier Therapeutics (BTRX) was acquired by privately-held Stiefel Labs

(4.) Pfizer's $164M cash buyout of cancer drug developer Coley Pharma (COLY)

(5.) Shionogi (Tokyo: 4507) recently closed its $1.4B cash buyout of Sciele Pharma (SCRX)

My guess as to who may be next is based on the following factors:

(1.) existing big pharma partnerships: Bayer + Onyx Pharma (ONXX)

(2.) high margin orphan drugs: Kuvan – BioMarin (BMRN) & Soliris – Alexion (ALXN)

(3.) revolutionary drug discovery technology platforms: RNAi for Isis Pharma (ISIS) & Alnylam (ALNY)

(4.) a late-stage pipeline + approved biological agents: Biogen (BIIB)

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (ALXN)

Avatar SuperStocker1 (84.00) Submitted: 8/14/08 11:45 PM : Outperform Start Price: $47.67 ALXN Score: 3.95

One word: Soliris, nice upwards trending also.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (ALXN)

Avatar pharmacist2011 (< 20) Submitted: 6/25/08 10:32 AM : Outperform Start Price: $35.25 ALXN Score: 33.62

From a screen

winner's from year
50 day Mov. Avg UNDER last price
Revenue Growth QvQ above 22
EPS Grwoth QvQ above 22

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (ALXN)

Avatar Colli002 (21.69) Submitted: 5/27/08 3:32 PM : Outperform Start Price: $33.82 ALXN Score: 41.65

the time is right - solid company

Report this Post Replies: 0 | Reply | Permalink

Recs

1

 (ALXN)

Avatar abetens2 (97.90) Submitted: 4/29/08 8:38 AM : Underperform Start Price: $35.03 ALXN Score: -37.98

Paroxysmal Nocturnal Hemoglobinuria -- extremely rare condition. Can Alexion justify an extremely high price for because of the rarity of the disease? Probably not. Notice that they are recording sales but not receiving cash. Their accounts receivables are going up, because they are not collecting payment. I think it will be very difficult to get insurance to cover soliris, especially at the current price-- if they do cover it, they will negotiate extreme discounts, e.g. paying only 20-30% of alexions's charge. Expect only about 30% of their accounts receivables to ultimately be converted to cash.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 13 :   1 2 3 Next »

Wall Street

Results 1 - 10 of 10  

picks per page. CHANGE

Top
Pick		Member NameMember RatingStart
Date		CallTime FrameStart
Price		Stock
Gain		S&P
Gain		ScorePitch
TrackCollinsStew 27.26 07/25/08 Outperform NS $40.18-5.00%-21.43%+16.43
TrackPiperJaff 72.70 05/29/08 Outperform NS $34.89+9.40%-28.86%+38.27
TrackJefferies < 20 05/14/08 Outperform NS $36.04+5.90%-29.86%+35.75
TrackUBS 81.43 01/29/08 Outperform NS $31.99+19.32%-27.33%+46.65
TrackCreditSuiss 76.59 10/26/07 Outperform NS $39.28-0.99%-41.23%+40.24
TrackBroadpointC 33.33 10/26/07 Outperform NS $39.28-0.99%-41.23%+40.24
TrackFerrisBaker 96.11 10/12/07 Outperform NS $35.72+8.86%-42.19%+51.05
TrackBofASec 93.40 10/05/07 Outperform NS $34.67+12.19%-41.98%+54.17
TrackCowenandCo 80.80 08/08/07 Outperform NS $30.90+25.86%-39.39%+65.25
TrackFirstAlbany 78.86 07/26/07 Outperform NS $29.15+33.44%-40.11%+73.55

Results 1 - 10 of 10  

X

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners